William Blair Starts Avalanche Biotechnologies (AAVL) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/12/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Cowen Starts Avalanche Biotechnologies (AAVL) at Outperform
August 25, 2014 7:11 AM EDTCowen initiated coverage on Avalanche Biotechnologies (NASDAQ: AAVL) with an Outperform rating and a price target of $45.00.
For an analyst ratings summary and ratings history on Avalanche Biotechnologies click here. For more ratings news on Avalanche Biotechnologies click here.
Shares of Avalanche Biotechnologies closed at $30.52 yesterday.
... MoreJefferies Starts Avalanche Biotechnologies (AAVL) at Buy
August 25, 2014 6:55 AM EDTJefferies initiates coverage on July IPO Avalanche Biotechnologies (NASDAQ: AAVL) with a Buy rating and a price target of $40.00.
Analyst Biren Amin said, "AAVL shares hold significant promise based on PI data with AVA-101 observing meaningful VA improvements and durable responses in wAMD... More
Piper Jaffray Starts Avalanche Biotechnologies (AAVL) at Overweight
August 25, 2014 6:53 AM EDTPiper Jaffray initiates coverage on July IPO Avalanche Biotechnologies (NASDAQ: AAVL) with a Overweight rating and a price target of $39.00.
Analyst Joshua Schimmer comments, "The company is among a handful of pioneers in the gene therapy field, and a leader among an even... More
